SCHAUMBURG, Ill., Feb. 25, 2016 -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leading provider of affordable pharmaceuticals to the hospital market, announced the hiring of Frank Harmon as Executive Vice President, Global Operations. In this newly created role, Mr. Harmon will oversee Sagent's Global Operations including Product Development, R&D, Manufacturing, Supply Chain, Regulatory and Global Alliance Management, with oversight support of Quality Assurance. Mr. Harmon will report directly to Allan Oberman, Sagent’s Chief Executive Officer.
"Mr. Harmon joins Sagent at an exciting time as we begin to execute against our “Triple E” strategy which is focused on accelerating our growth and enhancing our operational performance,” said Mr. Oberman. "Frank's extensive experience in pharmaceutical manufacturing and operations, with a proven history of success operating multiple injectable facilities, improving margins and managing complicated supply chains, will play an important role in accelerating our long-term growth trajectory and capitalizing on the favorable market opportunities that we see as critical to long-term value creation.”
Mr. Harmon has close to 40 years of pharmaceutical operations experience with companies including Fresenius Kabi, Cardinal Health, and Aventis-Behring (formerly Centeon LLC). Most recently, he served as Vice President, Operations of Nesher Pharmaceuticals (“Nesher”), a wholly owned subsidiary of Zydus Pharmaceuticals, where he was responsible for all manufacturing and contract packaging operations for generic solid dose and oral liquid products. Prior to joining Nesher, Mr. Harmon served as Chief Operating Officer and Executive Vice President of Fresenius Kabi USA, where he was responsible for managing a global network of parenteral manufacturing facilities and its global supply chain including supply from some of Sagent’s current partners. He earned an MBA degree from St. Louis University and holds a bachelor's degree in Biology and Chemistry from Western Kentucky University.
About Sagent Pharmaceuticals
Sagent Pharmaceuticals, Inc., founded in 2006, is a leading provider of affordable pharmaceuticals to the hospital market. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605


Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal
Meta Expands AI Training With Employee Activity Tracking Tools
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 



